The National Institute of Health and Care Excellence (NICE) have published new or updated guidance for the month of November 2018. This month there are two guidelines that impact upon primary care.
The Heavy menstrual bleeding guideline has been updated. The update reinstates recommendations on ulipristal acetate (Esmya®) following a European Medicines Agency review. Information on shared decision making and monitoring for side effects has been added for this treatment option.
The Urinary tract infection (catheter-associated): antimicrobial prescribing guideline has also been published. It sets out an antimicrobial prescribing strategy for catheter-associated urinary tract infection in children, young people and adults. It aims to optimise antibiotic use and reduce antibiotic resistance.
Last month several similar guidelines were issued that were not included in last month's post, they are as follows:
- Urinary tract infection (lower): antimicrobial prescribing
- Prostatitis (acute): antimicrobial prescribing
- Pyelonephritis (acute): antimicrobial prescribing
- Urinary tract infection (recurrent): antimicrobial prescribing
As above, each aims to provide an antimicrobial prescribing strategy that aims to optimise antibiotic use and reduce antibiotic resistance.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.
|« Cilest to be discontinued||Bricanyl Turbohaler Supplies Low »|